COMMUNIQUÉS West-GlobeNewswire

Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program
20/02/2024
Global thought leaders join advisory team to focus on Mestag’s groundbreaking tertiary lymphoid structure (TLS) induction approach to treat solid tumors CAMBRIDGE, United Kingdom, Feb. 20, 2024 (GLOBE NEWSWIRE) -- [...]
IntelGenx Launches Preferred Share Regulation A Offering
20/02/2024
SAINT LAURENT, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the launch of a Regulation A offering of up to 2,000,000 shares of Series A [...]
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
20/02/2024
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to [...]
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
20/02/2024
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
20/02/2024
COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, [...]
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
20/02/2024
ORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options Non-inferiority trial will [...]
Venus Concept to Release Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
20/02/2024
TORONTO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2023 [...]
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
20/02/2024
Publication pinpoints triggering of cGAS/STING pathway to activate immune defense mechanisms, as well as potentiation of anti-PD-L1 immune-mediated tumor cell killing, in triple-negative breast cancer xenograft model [...]
Theratechnologies annonce la publication d’un article dans Frontiers in Immunology qui approfondit la compréhension du mécanisme d’action moléculaire du sudocétaxel zendusortide (TH1902)
20/02/2024
MONTRÉAL, 20 févr. 2024 (GLOBE NEWSWIRE) -- L’article documente le déclenchement de la voie cGAS/STING, qui active des mécanismes de défense immunitaire et potentialise l’activité antitumorale de l’anti-PD-L1 dans un [...]
VitalHub UK Expands Healthtech Portfolio into Middle East through a Partnership with ADHDS
20/02/2024
TORONTO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF) and its subsidiary, VitalHub UK (“VitalHub UK”) are pleased to announce the expansion of its digital [...]
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
20/02/2024
NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b [...]
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
20/02/2024
- RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company [...]
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
20/02/2024
Vancouver, Canada, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic- [...]
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
20/02/2024
TEL AVIV, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders [...]
Emerging Markets Report: Look Who’s Talking
20/02/2024
Healwell’s Healthcare AI Getting Attention from the Right Sources An Emerging Markets Sponsored Commentary ORLANDO, Fla., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Those of us who write, edit, and publish The Emerging Markets [...]
Celcuity Appoints Eldon Mayer as Chief Commercial Officer
20/02/2024
MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer [...]
Kraig Biocraft Laboratories Announces New Premium Spider Silk and Pima Cotton Composite Yarn
20/02/2024
ANN ARBOR, Mich., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or "the Company"), announces the creation of its first premium yarn combining its recombinant spider silk [...]
Fortrea to Present at the Barclays 26th Annual Global Healthcare Conference
20/02/2024
DURHAM, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial [...]
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
20/02/2024
–   ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2) – – The Phase 1 trial of ARV-102 will evaluate safety, tolerability, [...]

Pages